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Abstract 
Following myocardial infarction (MI), the left ventricle (LV) undergoes a series of cardiac wound healing responses that 
involve stimulation of robust inflammation to clear necrotic myocytes and tissue debris and induction of extracellular 
matrix (ECM) protein synthesis to generate a scar. Proteomic strategies provide us with a means to index the ECM pro-
teins expressed in the LV, quantify amounts, determine functions, and explore interactions. This review will focus on 
the efforts taken in the proteomics research field that have expanded our understanding of post-MI LV remodeling, 
concentrating on the strengths and limitations of different proteomic approaches to glean information that is specific 
to ECM turnover in the post-MI setting. We will discuss how recent advances in sample preparation and labeling 
protocols increase our successes at detecting components of the cardiac ECM proteome. We will summarize how 
proteomic approaches, focusing on the ECM compartment, have progressed over time to current gel-free methods 
using decellularized fractions or labeling strategies that will be useful for clinical applications. This review will provide 
an overview of how cardiac ECM proteomics has evolved over the last decade and will provide insight into future 
directions that will drive forward our understanding of cardiac ECM turnover in the post-MI LV.
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ventricle, Matrikine
© 2016 The Author(s). This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
The left ventricle (LV) is a complex mixture of cell types, 
including cardiomyocytes, endothelial and vascular 
smooth muscle cells, fibroblasts, and immune cells, as 
well as extracellular matrix (ECM) that surrounds these 
cell types [1]. Due to the high metabolic demand placed 
on the myocardium, cardiac myocytes are high energy 
consumers with 30 % of their volume occupied by mito-
chondria [2]. Of the protein constituents in the LV, 
ECM components are present at lower concentrations 
than mitochondrial or cytoplasmic proteins and gener-
ally have lower solubility than intracellular components. 
Because of this, whole myocardial proteomics is predis-
posed to evaluating soluble intracellular proteins.
The cardiac ECM provides mechanical support to the 
LV, coordinates signal transduction, and regulates cell 
functions [3]. During myocardial infarction (MI), there 
is extensive extracellular protein turnover as old ECM is 
replaced by an infarct scar primarily composed of newly 
synthesized ECM. LV remodeling relies on a balance 
between ECM clearance and deposition. While excess 
degradation can lead to LV aneurysms or rupture, excess 
deposition can lead to a stiff LV that provides a substrate 
for the development of heart failure or arrhythmias [4–
6]. Evaluating ECM, therefore, is important for our com-
plete understanding of LV remodeling.
Over the last 10 years, proteomic capabilities have dra-
matically increased due to technological improvements, 
including enhanced sample preparation protocols and 
improved capabilities in mass spectrometry (MS), data-
base searching, and bioinformatics analysis of results. 
Combined, these improvements have made the evalua-
tion of cardiac ECM more approachable. In this review, 
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we will summarize the current state of the field and pro-
vide examples of how ECM proteomics is being used to 
better understand post-MI remodeling and to evaluate 
plasma and tissue samples from human subjects fol-
lowing MI. We will also borrow from the sepsis field to 
illustrate recent advances in glycoproteomics that have 
applicability for MI studies.
Indexing ECM proteins expressed in the LV
The first hurdle encountered was the fact that myocardial 
samples have a predominance of intracellular constitu-
ents, which made it very difficult to even identify ECM 
proteins, let alone quantify them. In the setting of MI, 
using samples that include the entire LV (both remote 
and infarct regions) focuses the evaluation on easily solu-
ble mitochondrial and cytoplasmic proteins. While the 
analysis of a whole tissue sample is the simplest method, 
this approach is not designed to focus on ECM.
To overcome this issue, we used another approach that 
takes advantage of the natural overabundance of collagen 
in the newly formed scar to target and enrich samples 
in ECM proteins. By day 7 post-MI, the infarct region 
is composed of 30  % collagen and can be easily visual-
ized by picrosirius red staining [7, 8]. We used this bio-
chemical property to our advantage and excluded the 
non-infarcted remote region during sample collection. By 
selecting only the infarct region and evaluating its protein 
composition by two dimensional gel electrophoresis (2DE 
gels), we were able to identify multiple ECM proteins, 
including fibronectin, laminin, peroxiredoxin-1, -2, and 
-3, tenascin-C, and thrombospondin-1 [9, 10]. Compar-
ing wild type mice to mice with global genetic deletions 
for matrix metalloproteinase (MMP) genes, we were able 
to identify several MMP-7 and MMP-9 substrates based 
on differences in expected and actual molecular weights 
[9–11]. Of these, fibronectin was demonstrated to be an 
in vivo MMP-7 and MMP-9 substrate in the infarcted LV. 
While this approach was an improvement over previous 
attempts using whole myocardial samples, the presence 
of a large amount of intracellular proteins still made the 
detection of lower abundance ECM proteins difficult.
To further remove the intracellular constituents and 
enrich for ECM, we and others have used decellulariza-
tion approaches, primarily involving the incubation of 
samples in 1  % sodium dodecyl sulfate (SDS) [12]. The 
Mayr laboratory developed a sequential extraction meth-
odology for cardiac ECM, which involves tissue decel-
lularization using SDS followed by re-solubilization and 
centrifugation to fractionate protein according to solu-
bility [13]. These investigators used this approach in a 
pig model of ischemia/reperfusion to identify for the 
first time novel ECM proteins that contribute to cardiac 
remodeling [14]. This list included cartilage intermediate 
layer protein 1, matrilin-4, extracellular adipocyte 
enhancer binding protein 1, collagen alpha-1(XIV), and 
several members of the small leucine-rich proteogly-
can family, including asporin and prolargin. Further 
analysis of over 100 ECM proteins revealed signatures 
of early- and late-stage cardiac remodeling, with trans-
forming growth factor-beta1 signaling at the epicenter of 
the interaction network. This biosignature of early- and 
late-stage ECM remodeling after myocardial ischemia/
reperfusion injury has clinical utility both as prognos-
tic markers and modifiable targets for drug discovery. 
Identifying different biosignatures in ECM remodeling 
post-MI could be used to determine whether a patient 
will recover and to what extent. Identifying patients with 
biosignatures that indicate insufficient or overly robust 
wound healing could be useful in determining which 
patients are at risk and need to be followed-up more 
closely and treated more aggressively.
Our team has also used this approach, which we termed 
the Texas 3 step protocol, to enrich for low-abundant 
and insoluble ECM proteins [12]. After decellulariza-
tion, we used acid extraction and enzymatic deglycosyla-
tion to enhance re-solubilization. The end output was 
the generation of three fractions consisting of proteins of 
decreasing solubility. The fact that these fractions were 
obtained using buffers that are MS-compatible allowed 
downstream proteomic analysis. One issue with using 
this approach for cardiac samples is that, due to the many 
fractionation steps with protein loss along the way, it is 
difficult to obtain reproducible quantification. While pro-
tein loss during extraction could be corrected by spiking 
the sample with a known standard, this approach is bet-
ter used for identification of the different types of ECM 
proteins present in a sample. Decellularization is more 
difficult to achieve in cardiac tissue compared to vascular 
tissue, where it has also been used to successfully iden-
tify ECM components and quantify major changes such 
as presence versus absence differences and substantial 
fold changes [13, 15]. Comparing across fractions pro-
vides details on ECM release, solubility, and interaction 
strength.
Quantifying amounts
Quantitation can be achieved using both label and 
label-free approaches [16, 17]. Of particular relevance 
to ECM studies, N-linked glycopeptides isolated from 
tryptic peptides using a solid phase extraction of glyco-
peptides (SPEG) method has been used to identify and 
quantify novel ECM changes in the post-MI setting [18, 
19]. Our team has recently employed the gel-free SPEG 
approach using lectin affinity chromatography to isolate 
out and quantify glycosylated proteins in both plasma 
and tissue samples [20–22]. Peptides were quantified 
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by label-free relative quantification based on integrated 
peptide peak intensities. This approach has the strength 
that it eliminates highly abundant, non-glycosylated 
proteins such as albumin. Enriching for glycoproteins is 
also advantageous when evaluating ECM, as ECM pro-
teins as a whole are highly glycosylated [20]. Of note, 
MMP catalytic sites contain a conserved N-linked gly-
cosylation site and do not contain O-linked glycans 
[23]. In the post-MI LV, glycoproteomics provides a 
powerful platform on which to identify and quantify 
N-glycosylated proteins important for LV remodeling 
[22]. Out of 541 N-glycosylated proteins quantified, we 
showed that CD36 is a novel substrate cleaved by MMP-
9, with important implications for macrophage phago-
cytosis in the MI setting. A limitation of this approach 
is that the differences in amounts refers to the amount 
of glycosylated protein and may not reflect total protein 
amounts. A change in glycosylation would register as 
a difference, while total protein concentration may be 
unchanged. As with any discovery proteomics work-
flow, SPEG requires validation by an independent tech-
nique such as multiple reaction monitoring, ELISA, or 
immunoblotting [24, 25].
In isolated cell culture, ECM secretion assessed by 
MS is termed secretomics. This gel-free approach has 
been used to evaluate miRNA effects on ECM secre-
tion by cardiac fibroblasts [26]. In this study, the 
secretome from mouse cardiac fibroblasts transfected 
with the pre-/anti-miR for miR-29b was analyzed by 
MS and quantified as spectral counts. The miR-29b 
targeted fibrosis-related proteins, including collagens, 
MMPs, leukemia inhibitory factor, insulin-like growth 
factor 1, and pentraxin 3 (PTX3). In the pre-miR-29b 
overexpression group, for example, fibulins 3 and 4 
and TIMP-2 were increased while collagen IA1 and 
IA2 and MMP-2 were decreased. After transfection 
with pre-miR-29b, the conditioned medium of cardiac 
fibroblasts lost the ability to support cardiac myocyte 
adhesion ex  vivo. This proteomic analysis revealed 
novel molecular targets of miRNAs linked to fibro-
sis. Such comprehensive screening methods are criti-
cal components for assessing cardiac ECM [26]. The 
Mayr laboratory has also used secretomics coupled to 
glycoproteomics to analyze the secretome of human 
endothelial cells, using a similar gel-free approach and 
quantifying using spectral counts [27]. This study pro-
vides the most comprehensive catalogue of endothelial 
protein secretion to date and demonstrates the poten-
tial of using a workflow that combines higher-energy 
C-trap dissociation with electron-transfer dissociation 
for a hybrid linear ion trap-orbitrap mass spectrometer 
that can determine the glycosylation status of complex 
biological samples.
Qualitative characterization
One issue with gel-free approaches is that molecu-
lar weight and pH information is not provided, which 
makes it more difficult to infer post-translational modi-
fications using unbiased approaches. Post-translational 
modifications relevant to ECM include cross-linking, 
glycosylation, and proteolytic processing by MMPs. 
MS techniques are currently robust enough to provide 
information on protein–protein interactions that occur 
over the time course of MI. Using global approaches for 
large-scale profiling can allow one to catalogue protein 
identities and relative concentrations. Identifying poten-
tial protein partners can then be followed up with other 
methodologies to provide validation. In order for the pro-
tein–protein interaction to be mapped using MS technol-
ogy, the intact protein complex needs to be first purified 
by affinity purification before digestion and MS analysis 
[28].
Proteomics can also be used to provide information 
about membrane topography [20]. The ECM proteome 
consists of all proteins expressed outside the cell, includ-
ing cell surface and secreted proteins; and due to their 
location, ECM proteins are highly amenable drug targets 
[29]. Information on protein location and availability can 
provide insight useful for selecting optimal antigen sites 
and identifying drug targets. One common feature that 
is highly desirable is easy accessibility, making ECM pro-
tein analysis highly relevant to drug development [30]. 
For this reason, efforts to determine the spatial orienta-
tion of target proteins have been undertaken. In addition 
to traditional methods for topology evaluation, mem-
brane protein site accessibility is becoming a useful tool 
to evaluate protein orientation. These methods include 
evaluation of N-glycosylation sites, antibody epitopes, 
iodinatable sites, and proteolytic sites [30]. Of these, 
N-glycosylation site assessment can be used for topology 
evaluation because N-linked glycosylation occurs only in 
extracellular domains of membrane proteins [31].
N-linked glycosylation site analysis can provide in vivo 
topologic evidence that has not been made available by 
other approaches. Zielinska and colleagues showed that 
glycosylation sites of membrane proteins always ori-
ent toward the extracellular space [32]. In fact, Gundry 
and co-workers used this concept to determine that the 
transmembrane glycoprotein ZIP14 had been assigned 
an orientation by Swiss-Prot that was incorrect, and this 
annotation has since been corrected [31]. We have used 
a similar approach to identify 1352 unique N-linked gly-
cosylation sites and provide new topologic information 
on hundreds of ECM proteins [20]. In the β1 integrin, 
for example, there were 14 predicted N-linked glycosites, 
with only four having been previously identified (N363, 
N366, N376, and N669). We identified four novel 
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N-glycosites for β1 Integrin (N212, N406, N481, and 
N520) that have recently been confirmed by other groups 
[33, 34]. These sites are distributed throughout the pre-
dicted extracellular domain, which validates this section 
being extracellular and helps to eliminate false positives.
Adapting these approaches to clinical samples
Using proteomics to analyze clinical samples shares 
many of the same technical considerations as pre-clini-
cal studies. In assessing feasibility, there are factors that 
should be taken into account, including the scope of the 
intended study (broad or targeted) for which different 
technologies may be used. This, in turn, will also influ-
ence downstream factors, such as the number of groups 
to compare and the number of replicates that can be 
processed in a manageable experiment. These considera-
tions are listed in Table 1 and include criteria for subject 
selection, sample type, collection method, sample storage 
conditions, data acquisition and analysis methods, and 
results documentation.
Reproducibility and replication assessment
The first step involves assessing project feasibility and 
developing a careful experimental design. In terms of 
project feasibility, a major consideration is how to har-
ness the experiment to keep acquisition, analysis, and 
data interpretation feasible. If there are a large number 
of expected output measurements, limiting the number 
of inputs (e.g. group number) will help to maintain fea-
sibility and provide adequate power for statistical analy-
sis. Experimental designs that compare more than four 
groups often suffer from power that is reduced to below 
acceptable limits and make the experiment unwieldy. For 
example, it would be better to have 2 groups with n = 10 
per group than 4 groups with n = 5 per group. Increas-
ing the biological replicates for the MS analysis can be 
coupled to downstream validation experiments, such as 
enzyme-linked immunosorbent assay or immunoblot-
ting, which can more easily accommodate additional 
controls. If using a targeted proteomics approach with 
a limited number of expected outputs, then the number 
of inputs can be increased to include a broad number of 
controls. Targeted proteomics refers to the analysis of a 
preselected group of proteins [35]. As techniques evolve, 
the use of population scale proteomics will be possible 
for the more general proteomics lab.
Sample collection and storage
Other considerations for experimental design are sam-
ple collection and storage conditions and potential solu-
bility issues. With many clinical cohorts, samples were 
collected before we understood the importance of col-
lecting samples in protease inhibitors. There have been 
considerable efforts made to develop uniform collection 
standards for plasma proteomics experiments to improve 
both reproducibility and replication. As part of the 
Human Plasma Proteome Project, evaluation of serum 
and plasma samples collected under a variety of condi-
tions showed that EDTA anti-coagulated plasma samples 
gave the most reproducible results [36]. Of note, how-
ever, the results of this study were highly variable, in part 
due to a lack of laboratory selection criteria and analyti-
cal standards to assess results quality. Another issue with 
this approach is that by developing a global approach, 
individual priorities may not be met. Downstream appli-
cations often require the use of a specific reagent. For 
example, MMPs are best studied in plasma samples col-
lected with heparin as the anti-coagulant, because EDTA 
inhibits MMP activity [37, 38]. Therefore, plasma pro-
teomics for ECM may not be entirely compatible with 
a general consensus protocol. If the amount of sample 
is not a limiting factor, we recommend using multiple 
recovery techniques in a protocol (e.g. obtain two blood 
samples from the same individual: one in a heparinized 
tube and another in an EDTA-treated tube) to maximize 
the amount of information that one can obtain. In addi-
tion, because the plasma potentially reflects changes 
across all organs, determining cardiac source or cardiac 
relevance is important.
In terms of storage, samples should be matched across 
groups in regards to storage conditions, including length 
and temperature. If storage has been prolonged, evaluat-
ing the sample condition (e.g., by running 10 μg total pro-
tein on a 1DE gel to assess for degradation) is crucial. For 
tissue samples, many ECM proteins are highly insoluble, 
and buffer selection for protein extraction is important 
and depends on the question being addressed. Consid-
eration should be given for whether samples are imme-
diately analyzed after collection or stored and examined 
as batch analysis. While analyzing immediately would 
remove variation due to storage times, whether analy-
sis can be grouped across batch runs would need to be 
assessed by the individual proteomics facility and would 
need to include robust statistical support. In our studies, 
we have not compared results across batches, but rather 
Table 1 Experimental design considerations for  clinical 
studies. Modified from [39]
Criteria for subject selection
Type of samples and method of collection
Storage conditions of the sample
Methods of data acquisition and analysis
Documentation of results
Reproducibility and replication assessment
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have collected samples in protease inhibitor cocktail to 
minimize degradation during storage.
If enrichment is needed to quantify lower abundance 
proteins, the buffer used may differ from that used for 
experiments where the goal is to provide an inventory of 
all proteins present in the sample. This is not a concern 
for plasma samples, since the proteins are already in a 
soluble media.
Once the experimental design is developed, down-
stream acquisition, analysis, and validation are the final 
steps. Considerations for these components of the 
experiment have been well described elsewhere [39–41]. 
Below, we provide examples of how cardiac ECM prot-
eomics has been used in clinical studies. We and others 
have used proteomics in translational research to cata-
logue proteins present during pathology, as well as to 
determine protein functions and explore protein–protein 
interactions.
Applications
We have used the natural overabundance of ECM pro-
tocol to identify a novel MMP-9 cleavage site on col-
lagen I (at amino acids 1158/1159) in the LV infarcts of 
mice [11]. We took this observation and showed that a 
fragment was generated by MMP-2 and MMP-9, with 
MMP-9 further degrading it. ECM fragments that are 
generated by proteolysis or other processing and have 
biological activity in addition to or distinct from the 
parent ECM protein are termed matrikines or matric-
ryptins [42]. To test whether the collagen matrikine 
had signaling activity, a peptide 20 amino acids down-
stream of the cleavage site was generated and tested for 
in  vitro and in  vivo activity. Fibroblasts stimulated with 
this peptide showed enhanced wound closure properties. 
Human umbilical vein endothelial cells stimulated with 
the p1158/59 peptide, but not the spanning peptide, has 
increased tube formation. Injection of the p1158/59 pep-
tide at 3 h post-MI attenuated LV dilation by promoting 
angiogenesis and limiting myofibroblast activity. Injec-
tion of this peptide at 3 h post-MI attenuated LV dilation 
by promoting angiogenesis and promoting myofibroblast 
wound healing activity. In humans with MI, higher con-
centrations of this collagen fragment associated with 
improved LV function. This set of experiments provides a 
template on which to design proteomics studies to evalu-
ate additional ECM matrikines generated by MMPs post-
MI (Fig. 1).
Decellularization has been used to evaluate the ECM 
composition of human samples, including samples 
from human abdominal aneurysms and other vascular 
pathologies [14, 15, 43–46]. The Mayr laboratory has 
used this approach coupled with sequential extraction 
to identify hundreds of ECM proteins in human aortas, 
human abdominal aortic aneurysms, and human LV from 
patients with ischemic cardiomyopathy [13–15, 45, 47]. 
This team has been the first to report the presence of 
more than a dozen ECM proteins not previously identi-
fied in the myocardium. By combining protein signature 
evaluation during both acute and chronic remodeling 
time points with protein network interaction analysis, 
Mayr and colleagues identified transforming growth fac-
tor β1 as being a pivotal regulator of ECM remodeling 
induced by ischemia and reperfusion [14]. Decellulariza-
tion approaches provide an unbiased first pass method to 
focus on ECM changes that are cause and consequence of 
LV remodeling.
Our team used glycoproteomics to show that sepsis out-
comes are linked to the activation of distinct proteins pre-
sent in the blood coagulation pathways [21]. In our cohort 
of 20 patients, we evaluated plasma collected at the time 
of admission and subdivided groups based on survival 
outcomes. We identified 234 glycoproteins; of which 54 
were unique to the survivor group, 43 were unique to the 
non-survivor group, and 137 were common responses 
between groups. By immunoblotting, plasma samples 
from non-survivors showed elevated total kininogens and 
reduced total cathepsin-L1, vascular cell adhesion mol-
ecule, periostin, neutrophil gelatinase-associated lipoca-
lin, and glycosylated clusterin compared to the survivor 
group. Kyoto Encyclopedia of Genes and Genomes analy-
sis revealed that survivors relied on the extrinsic pathway 
of the complement and coagulation cascade, while non-
survivors relied on the intrinsic pathway.
Cuello and colleagues used an endotoxemic mouse 
model coupled to a tissue-based proteomics approach for 
biomarker discovery and identified PTX3 as a lead can-
didate for inflamed myocardium during sepsis [48]. They 
found that PTX3 accumulation as an octamer was due 
to disulfide-bond formation, which was present in heart, 
kidney, and lung. Of interest, PTX3 oligomeric moieties 
were also detectable in the circulation. They expanded on 
these results in their animal model to demonstrate that 
from day 2 after admission, octameric to monomeric 
PTX3 conversion consistently associated with a greater 
survival after 28  days of follow-up. Further, monomeric 
PTX3 was inversely associated with the extent of cardiac 
damage, indicated by elevated NT-proBNP and high-
sensitivity troponins I and T. Relative to the conventional 
measurements of total PTX3 or NT-proBNP, the oli-
gomerization of PTX3 showed superior performance in 
predicting disease outcomes. This provides an excellent 
example of how to start with a proteomics observational 
experiment and carry it forward to provide mechanistic 
links.
The Overall laboratory has successfully used terminom-
ics analysis of protease cleavage sites as a degradomics 
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substrate discovery platform [49]. This approach uses termi-
nal amine isotopic labeling of substrates (TAILS) as a high-
throughput method to identify protease-generated neo-N 
termini. Using negative selection, the TAILS approach first 
enriches for all N-terminal peptides and then uses pri-
mary amine labeling-based quantification to discriminate. 
N-terminal and lysine amines are blocked by dimethylation 
(formaldehyde/sodium cyanoborohydride) and labeled for 
relative and absolute quantification. After tryptic digestion, 
a high molecular weight dendritic polyglycerol aldehyde 
polymer binds the internal tryptic and C-terminal peptides, 
which now have N-terminal alpha amines. This provides 
the means for N-terminal peptide separation. The unbound 
naturally blocked peptides are recovered by ultrafiltration 
and analyzed by tandem mass spectrometry (MS/MS). This 
labeling approach is versatile and well-suited to a broad 
range of applications, including in vitro cell culture analy-
ses and in vivo tissue analyses. Hierarchical substrate win-
nowing can be used to subtract out background proteolysis 
products and non-cleaved proteins.
In translational studies, proteomics often serves as the 
beginning experiment from which to base a mechanistic 
evaluation of the system. With clinical samples, proteom-
ics often serves as the final experiment from which to 
evaluate outputs in a trial or to identify novel biomarkers 
that can then be taken back into basic science projects in 
reverse translational study applications.
Conclusions and future directions
Table 2 summarizes the evolution of approaches we and 
others have taken over the years to evaluate the cardiac 
ECM proteome and provides strengths and limitations 
for each approach. The best approach will depend on 
the question being asked, and experimental designs 
can vary depending on the importance placed on more 
complete cataloguing, quantification, or assessing tar-
geted protein quality. Often, a combination of methods 
is used through a study to provide a more comprehen-
sive assessment. For example, 2DE gel analysis for first 
pass identification is often a great starting point, with 
targeted proteomic strategies used as follow-up experi-
ments to provide mechanistic insight. Of note, the need 
for bioinformatics is important, in order to process 
the massive amount of data generated from proteomic 
approaches.
In conclusion, methods to catalogue cardiac ECM 
using proteomics technologies have dramatically 
improved over the last 10 years. Current research in the 
post-MI cardiac ECM field is focused on defining the 
mechanistic roles for these identified proteins. Of par-
ticular importance are the signaling cascades initiated by 
ECM matrikines generated by MMP proteolysis. In the 
clinical field, translation of both these approaches and 
findings will help to identify novel targets and mecha-
nisms of post-MI remodeling.
Template for identifying and testing mechanisms of ECM matrikines
2DE gel analysis of tissue to identify candidate substrates
In vitro cleavage assays and MS to confirm substrate & identify cleavage sites
full length protein 
spanning peptides
In vivo monitoring of matrikine formation
generate cleavage specific antibodies
Generate matrikine peptides upstream/downstream of cleavage site
in vitro assessment of cell response (individual & combination)
in vivo assessment of post-MI response
Determine cell signaling stimulated by matrikine peptides
identify receptor(s) involved




Fig. 1 An example of one project work flow for extracellular matrix proteomics experiments that start with 2DE-gel evaluation and mass spectrom-
etry experiments and culminate with functional assays to provide mechanistic insight
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